Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis Inc. reports biotechnology developments centered on emavusertib (CA-4948), an orally available small-molecule IRAK4 and FLT3 inhibitor. Company updates focus on oncology programs in lymphoma, chronic lymphocytic leukemia and acute myeloid leukemia, including clinical data presentations, combination approaches with BTK inhibitors, and studies involving venetoclax and azacitidine.
Recurring Curis news also covers quarterly financial and operating results, conference-call updates, capital actions such as private placements, and security-structure matters involving preferred stock and warrants. The company’s public updates combine clinical-program progress with financing, governance and operating disclosures typical of a development-stage biotechnology issuer.
Curis, Inc. (NASDAQ: CRIS), a biotechnology firm focusing on cancer therapeutics, will have its CEO James Dentzer present at the 21st Annual Needham Virtual Healthcare Conference. This presentation will be available for on-demand viewing starting April 12, 2022, at 8:45 a.m. ET. Investors can access a live webcast on the company's website, with a replay available for 90 days post-event. Curis is known for its collaborations in immuno-oncology and its ongoing clinical trials for therapies like emavusertib, aimed at non-Hodgkin's lymphoma and acute myeloid leukemia.
Curis, Inc. (NASDAQ: CRIS) announced a partial clinical hold by the FDA on its TakeAim Leukemia Phase 1/2a study due to safety concerns, particularly related to a patient fatality involving rhabdomyolysis, a known toxicity of emavusertib (CA-4948). While no new patients will be enrolled during this hold, current participants may continue treatment with lower doses. The FDA requires additional data on safety and efficacy before the study can resume. This hold does not affect the TakeAim Lymphoma study, but Curis has paused enrollment in that trial as well.
Curis, Inc. (NASDAQ: CRIS) announced the publication of a manuscript in Gastroenterology, detailing the role of IRAK4 in pancreatic ductal adenocarcinoma (PDAC) and the preclinical efficacy of the IRAK4 inhibitor emavusertib (CA-4948) combined with checkpoint immunotherapy. The study indicates that targeting IRAK4 could counteract tumor-induced T-cell exhaustion and improve responses to treatment. The research suggests potential broader applications of emavusertib in solid tumors, highlighting its promise in addressing significant unmet patient needs in cancer therapeutics.
Curis, Inc. (NASDAQ: CRIS) reported its Q4 2021 financial results, showing a net loss of $13.6 million or $0.15 per share, compared to a net loss of $7.5 million in Q4 2020. Total revenues for 2021 were $10.6 million, slightly down from $10.8 million in 2020. Notably, Curis announced promising clinical progress in its pipeline, particularly for emavusertib (CA-4948) in leukemia treatment, and favorable safety data for CI-8993. The company plans to discuss a rapid FDA registration path and continues to see operational growth with new executive appointments.
Curis, Inc. (NASDAQ: CRIS) will release its Q4 2021 financial results on February 24, 2022, after U.S. markets close. Management will host a conference call at 4:30 PM ET on the same day. Investors can join the call by dialing (888) 346-6389 (U.S.) or (412) 317-5252 (international). The call will also be available on Curis's website. The company specializes in cancer therapeutics, and its pipeline includes the IRAK4 kinase inhibitor CA-4948, currently in clinical trials for various hematologic malignancies.
Curis, Inc. (NASDAQ: CRIS) announced that CEO James Dentzer will participate in two upcoming conferences: the B. Riley Virtual Oncology Conference on January 27, 2022, at 1:30 p.m. ET, and the SVB Leerink 11th Annual Global Healthcare Conference on February 18, 2022, at 11:20 a.m. ET. Live webcasts of these presentations will be accessible on their website, and archived replays will be available for 90 days afterward.
Curis focuses on innovative cancer therapeutics, including trials on the IRAK4 inhibitor CA-4948.
Curis, Inc. (NASDAQ: CRIS) announced the approval of inducement stock options on January 3, 2022, granting 224,700 shares to eleven new employees. The options have a 10-year term, with vesting over four years based on continued employment. Each grant's exercise price matches the stock's closing price on the grant date, incentivizing new hires as part of the company's growth strategy in cancer therapeutics. Curis focuses on innovating treatments, particularly in immuno-oncology, with several clinical trials underway for its drug candidates.
Curis, Inc. (NASDAQ: CRIS) announced positive clinical data from its ongoing Phase 1/2 study of CA-4948, an IRAK-4 inhibitor, for treating relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). As of December 16, 2021, CA-4948 was well-tolerated, with no dose-limiting toxicities reported, and showed promising anti-cancer activity with a 40% complete response rate in AML patients with specific mutations. Curis also reported initial positive safety data for CI-8993, a monoclonal antibody targeting VISTA, currently in Phase 1 trials for solid tumors.
Curis, Inc. (NASDAQ: CRIS) announced the appointment of three new executives to enhance its management team as of January 3, 2022. Felix Geissler, M.D., Ph.D., becomes Vice President of Medical Affairs; Kimberly Steinmann, M.D., Vice President of Clinical Development; and Dora Ferrari, Vice President of Clinical Operations. These appointments aim to bolster internal capabilities for advancing clinical drug candidates CA-4948 and CI-8993. The company is focused on developing innovative cancer therapeutics and has collaborations for its drug candidates, including ongoing trials.
Curis, Inc. (NASDAQ: CRIS) announced that CEO James Dentzer will present at the H.C. Wainwright BioConnect Conference on January 10, 2022, starting at 7:00 a.m. ET. The presentation will be available for on-demand viewing afterward. A live webcast can be viewed in the Investors section of Curis' website and will remain accessible for 90 days. Curis focuses on developing cancer therapeutics, including collaborations on various oncology treatments, such as the IRAK4 inhibitor CA-4948, currently in trials for non-Hodgkin lymphoma and acute myeloid leukemia.